Literature DB >> 30134369

Brinzolamide-induced Follicular Conjunctivitis.

Jonathan W Young1, John L Clements1, John C Morrison1, Hana L Takusagawa1,2.   

Abstract

We report a case of a patient who developed a severe case of follicular conjunctivitis from brinzolamide after 1.5 years of consistent use. This patient was rechallenged again after resolution of the follicles and subsequently redeveloped similar conjunctivitis. This is the first confirmed reported case of follicular conjunctivitis from brinzolamide use.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30134369      PMCID： PMC6218271          DOI： 10.1097/IJG.0000000000001063

Source DB:  PubMed          Journal:  J Glaucoma        ISSN： 1057-0829            Impact factor:   2.503


  4 in total

1.  The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.

Authors:  W F March; K I Ochsner
Journal:  Am J Ophthalmol       Date:  2000-02       Impact factor: 5.258

2.  Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.

Authors:  L Jay Katz
Journal:  J Glaucoma       Date:  2002-04       Impact factor: 2.503

3.  Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.

Authors:  Gianluca Manni; Marco Centofanti; Marta Sacchetti; Francesco Oddone; Stefano Bonini; Mariacristina Parravano; Massimo Gilberto Bucci
Journal:  J Glaucoma       Date:  2004-04       Impact factor: 2.503

4.  Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.

Authors:  L H Silver
Journal:  Am J Ophthalmol       Date:  1998-09       Impact factor: 5.258
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.